key: cord-1024598-4ctsp5r7 authors: Lu, Chun-Li; Zheng, Ruo-Xiang; Xue, Xue; Zhang, Xiao-Wen; Liu, Xue-Han; Jin, Xin-Yan; Pu, Feng-Lan; Lan, Hui-Di; Fang, Min; Kong, Ling-Yao; Willcox, Merlin; Graz, Bertrand; Houriet, Joelle; Hu, Xiao-Yang; Liu, Jian-Ping title: Traditional Chinese medicine for COVID-19 pandemic and emerging challenges: An online cross-sectional survey in China date: 2021-10-19 journal: Integr Med Res DOI: 10.1016/j.imr.2021.100798 sha: 483154a94e16c5784fbcd71be11906fa40d590f5 doc_id: 1024598 cord_uid: 4ctsp5r7 BACKGROUND: : We aimed to investigate use of infectious control behaviours, preventative and therapeutic interventions, and outcomes among respondents to an online survey during the COVID-19 pandemic in China. METHODS: : The survey was designed by an international team, translated and adapted to simplified Chinese, with 132 kinds of traditional Chinese medicine (TCM) preparation recommended by guidelines added. It was distributed and collected from February to May 2021, with data analysed by WPS spreadsheet and wjx.cn. Descriptive statistics were used to describe demographics and clinical characteristics, diagnosis, treatments, preventative behaviours and interventions, and their associated outcomes. RESULTS: : The survey was accessed 503 times with 341 (67.8%) completions covering 23 provinces and four municipalities in China. Most (282/341, 82.7%) respondents reported no symptoms during the pandemic and majority (290/341, 85.0%) reported having a SARS-CoV-2 PCR test at some point. 45 (13.2%) reported having a respiratory infection, among which 19 (42.2%) took one or more categories of modern medicine, e.g. painkillers, antibiotics; 16 (35.6%) used TCM interventions(s); while seven respondents combined TCM with modern medicine, coming out improvement and recovery. All respondents reported using at least one behavioural or medical approach to prevention, with 22.3% taking TCM and the 5.3% taking modern medicines. No respondents reported having critical condition related to COVID-19. CONCLUSION: : We found evidence of widespread use of infection control behaviours, modern medicines and TCM for treatment and prevention of COVID-19 and other respiratory symptoms. Larger scale studies including a more representative sample exploring TCM preparations recommended in clinical guidelines are warranted. Coronavirus disease is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Until September 13 th 2021, there have been more than 224 million confirmed cases, including 3 million deaths reported on the World Health Organisation website [1] . Most people diagnosed with COVID-19 experienced mild to moderate respiratory illness and the most common symptoms include fever, dry cough and tiredness [2] [3] [4] [5] [6] [7] . As for current treatments of COVID-19 patients with mild symptoms, WHO guidelines recommend that they should be isolated and given symptomatic treatment including antipyretics for fever and pain, adequate nutrition and appropriate rehydration [8] . Differing from WHO guidelines, Chinese guidelines recommend not only the symptomatic and anti-viral treatments, but also traditional Chinese medicine (TCM) such as Qingfeipaidu Decoction and Hanshiyi Decoction [6] [7] . For people with severe or critical , current evidence indicates that corticosteroids, remdesivir, hydroxychloroquine, lopinavir/ ritonavir and interferon may have some effects on overall mortality, initiation of ventilation and duration of hospital stay [8, [10] [11] [12] [13] . For public health and suspected cases, quarantine is an effective way to reduce the transmission of COVID-19 and other pandemics [14] . Other behavioural control methods, such as physical distancing, wearing a mask, hand washing, keeping rooms well ventilated, avoiding crowds, and coughing into a bent elbow or tissue could also be effective [15] . At the same time, nearly 300 vaccines are being developed, among which eight have been used worldwide [16] . In China, there are mainly three categories of vaccines with completion of over two billion doses vaccination [17] , including inactivated SARS-CoV-2 vaccine (Vero cell) [18] [19] [20] [21] , recombinant SARS-CoV-2 vaccine (Type 5 adenovirus vector) [22] , and recombinant SARS-CoV-2 vaccine (CHO cell) [23] . However, the evaluation of effectiveness and safety of these vaccines are still ongoing, and their impact on mutated virus variants remains to be seen [24] [25] [26] . TCM has been proved to help enhance the body's resistance (Zheng qi) to infectious diseases based on clinical studies and experiments [27] [28] [29] . Therefore, considering the need for more evidence, we collaborated with international researchers to investigate behavioural changes, preventative and therapeutic interventions, their occurrence and outcomes among the Chinese population during the COVID-19 pandemic. We aimed to conduct this online crosssectional survey to show the general situation during pandemic in China and to indicate the further challenges to fight COVID-19. -6 - The content of study was reported following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement [29] , and the findings was reported following the Checklist for Reporting Results of Internet E-surveys checklist (CHERRIES) [31] . The study design and data management method are as following. An international retrospective survey of prevention, treatment, occurrence and outcomes of Covid-19 in the community involving 14 countries was led by the researchers in University of Southampton (UoS). The original survey questions as the English version (available at: https://www.rtocovid19.com) were translated and indigenized by the authors in Beijing University of Chinese medicine since 10 th May, 2020. Localisation was made to reflect the tendency of Chinese people to prevent and cope with diseases, and to adapt to China's anti-epidemic policies and vaccine market. After gaining the contact information from the respondents, we also conducted a three-month follow-up questionnaire to acquire more information on peoples' changes based on this cohort baseline. All potential participants were able to access the website of this survey. In those cases where participants were unable to answer the questions themselves, their family members or friends were also invited to help them complete the survey. There was no man-made selective bias on participants. The questionnaire was disseminated by authors and other academic research groups. Inclusion criteria: 1) Any person who could access the questionnaire online; 2) Any person who can read and understand the questionnaire; 3) Person checked "agree" on the informed consent page, to present information on preventive behaviours, treatments taken, symptoms of respiratory illness and their clinical outcomes. 4) There was no restriction on gender. 5) For children (<16), their parents were invited to complete the questionnaire. Exclusion criteria: Person lacking mental capacity to understand the questionnaire were excluded. This study received ethical approval from BUCM (2020BZYLL0501, Sep 2020) and from UoS (ERGO 56975, May 2020). All participants were invited to read the overview of the survey. Only those who confirmed consent by clicking the button "I agree" at the beginning proceeded to the questions. No personal privacy information was collected, and all data collected were managed by the Chinese team. Questions in simplified Chinese (GBK) version were adjusted to fit the context in China, especially adding more information on TCM. Firstly, machine translation was applied for the original English version questionnaire. Secondly, four authors edited the questionnaire word by word to improve readability. Thirdly, the questionnaire was designed on wjx.cn. Fourthly, all authors piloted the survey with different test scenarios, to improve the logic and phrases. This was repeated seven times before the questionnaire was finalized. Questions or answers were changed according to the habits and situation in China, for example, replacing medications (such as "Dafalgan®" to "Tylenol®, "Cetallerg®" to "Zyrtec®") or medical system e.g. Ayurveda interventions were removed because they are rarely used in China. The content of Chinese patent medicine was expended because of the common use of TCM in China. The Chinese medicines were identified from both national and provincial TCM guidelines to alleviate symptoms of COVID-19, including three versions of national guidelines, Beijing version, three versions of Hunan province, two versions of Guangdong province, Shaanxi province version, Jiangxi province version, Liaoning province version, Sichuan province version, Hebei province version, Gansu province version, Guizhou province version [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] . To reduce the difficulty and time cost of filling the questionnaire, we categorized 132 recommended TCM preparations according to their dosage forms, details in supplementary table 1. With the development of the COVID-19 vaccine, we also added the latest information regarding vaccination. The survey was issued on a survey platform wjx.cn. Each person had only one account to answer the questions. The questionnaire was tested by all Chinese authors before dissemination, and considering the different logical relationships between questions. All authors also piloted the questionnaire using different scenarios. The open questionnaire was released on wjx.cn from February 6to May 19, 2021. The authors forwarded the WeChat post (designed with QR code) to their friends as snowball sampling. The authors contacted five academic organisations to help disseminate the post to more possible respondents. The survey advertisement attached the questionnaire link and the main content of the survey was posted on WeChat subscription account (ebcm2016). People could access from WeChat and Weibo (social platform). Participants who agreed to give their contact details were asked to complete the follow-up questionnaire after three months. As a public survey platform, wjx.cn has no internet barriers to visit. When the respondents submitted their answers, they could get a lottery supported by wjx.cn without any conflict of interest. To prevent bias, answers to the questions were arranged in random order. We designed 39 sections including 226 question-items per page, and also added one page of welcome and one page of thanks. Respondents could skip some questions due to the logic and their conditions. Considering the possible multiple options, we only set the informed consent as the mandatory item. Each respondent could review the answers but could not change any content once they submitted. The primary outcomes including summary of: 1) response rates 2) basic characteristics (physical and mental conditions, COVID-19 impact on social situation) 3) diagnosis (detection of COVID-19 and related respiratory symptoms) 4) treatments and outcomes (for the respiratory symptoms during first and second week) The secondary outcomes were the similar contend from from follow-up questionnaire after three-months, including the response rates, basic characteristics, treatments and outcomes and preventive measures. wjx.cn supported the identification of unique visitor who visited the webpage multiple times with the same IP addresses. wjx.cn could calculate the unique first survey page visitors, participant rate and completion rate. The participants could only be withdrawn by contacting the investigators and asking to be removed from the study. All participants were free to stop at any time and not to complete the survey. Data were managed in WPS spreadsheet and analysed with wjx.cn (https://www.wjx.cn/). Descriptive analysis was used for basic physical and mental conditions, detection of COVID-19 and related symptoms, treatment for respiratory symptoms, measures to prevent the spread, testing and vaccination of COVID-19, general social information, and the follow-up questionnaire, presented as numbers and percentages. If a questionnaire was collected successfully, we regarded this answer as a complete respondent. Missing data in the analysed items were presented as nonvalues. The survey was available online from Feb. 6, 2021 to May 19, 2021 and collected a total of 503 visit times, among which 341 (67.8%) submitted their answers. The basic information of the respondents was provided in Table 1 . The data were collected from 23 provinces and four municipalities in China (including Taiwan and Hong Kong, no sample from Macao), and we removed the data when the participants were not live in main land China, and distribution map covering 316 respondents' report was shown in Figure 1 , the detailed numbers in supplementary table 2. As for the follow-up survey after three-months, we gave out the questionnaire also via wjx.cn to 155 respondents separately who were willing to be followed up and provided their contact information on July 2, 2021. Finally, 23 respondents answered the follow-up questionnaire. This section of the questionnaire mainly involved chronic diseases, pregnancy, taking drugs, and mental health. 82.7% respondents had no chronic diseases or mental illness, and 17 respondents reported mental health conditions, details in Table 1 The majority of the respondents (291/341, 85.4%) did not take any medication during COVID-19, and the others took some medicine such as anti-hypertensive drugs, statins, thyroxine, immunosuppressor, anti-allergic agent and traditional Chinese medicine due to their long-standing chronic diseases. Regarding the economic situation, only few (12/341, 3.5%) participants did not provide an answer. Among those who did respond, 38.9% (128/329) believed that COVID-19 influenced their lives, and more than half (201/329, 61.1%) did not think COVID-19 has impact. 138 respondents were health care workers and the rest of other people's working status and occupations during the epidemic were shown in Table 1 . Twenty-eight respondents reported their behaviours changed due to COVID-19, details in Table 2 . As for the 23 respondents from the follow-up questionnaire after three-month, their behavioural changes were also shown in Table 2 . Up to the time of responding to the questionnaire, 85.0% respondents had completed a PCR test for COVID-19. Six respondents had been infected with SARS-COV-2 and the others (284/290, 97.9%) had a negative result, details in Table 1. 86.8% (296/341) respondents had not developed any respiratory symptom since the beginning of the COVID-19 outbreak. 13.2% (45/341) respondents had experienced respiratory symptoms and their common symptoms are shown in Figure 2 . The respiratory symptoms influenced the patient's normal lifestyle to a maximum of 28 days, with an average of 5.95 days. These 45 respondents reported that their symptoms caused varying degrees of discomfort as the average of the score was 4.17 (Score of 0 is the best and 10 is the worst). The average score for concern about their illness was 3.29 (Score of 0 is no concerns and 10 is extremely concerned). 60.0% (27/45) of them recovered completely with symptoms disappeared after one and two weeks, and others' outcomes including improvement, no improvement, and deterioration see in Table 6 . Forty-five respondents with respiratory symptoms reported their therapeutic treatments and thirty respondents reported prescription methods during the first week of their illness, detailed in Table 4 and Table 5 , including mainly four types, such as modern medicine, TCM, other treatment and no treatment. The most common method they got the medicine was selfcare/self-medication (17/45, 37.8%). Seven respondents combined Chinese herbal preparation or acupuncture together with modern medicine. TCM included seven kinds of Chinese herbal preparation, acupuncture and moxibustion. In terms of access to antibiotics, 66.7% (6/9) obtained by prescription from a professional, 22.2% (2/9) used what was left over from the past and 11.1% (1/9) bought it from Internet. The treatments were used after an average of 2.66 (1-7) days of symptoms (available data from 30 respondents). Only three respondents reported that they were in the hospital for 5.5 (1-10) days on average, and they had been discharged at the time of filling out the questionnaire. Only one respondent reported confirmed as COCID-19 by SARS-CoV-2 PCR tests, the other two did not reported other chronic diseases or any reasons for being in the hospital. No one was in intensive care, and no one was on a ventilator. All respondents had improved and recovered after one or two weeks, details in Table 6 . In terms of the 23 respondents from the follow-up questionnaire after threemonth, two respondents reported that they had new respiratory symptoms, and their treatment and prevention were shown in supplementary table 5. Among these 45 respondents, they failed to get SARS-CoV-2 PCR test when they had respiratory symptoms in 2020, so seven respondents suspected to be infected with COVID-19 and they made possible behavioural changes to prevent the potential spread since 2020, details in Table 2 . However, up to the time of responding to the questionnaire in 2021, 28.9% (13/45) respondents reported as both negative SARS-CoV-2 nucleic acid test and negative antibody testing of COVID-19, and only one respondent reported as both positive. Two respondents reported as positive SARS-CoV-2 nucleic acid test but negative antibody testing of COVID-19, and one respondent reported as negative SARS-CoV-2 nucleic acid test but positive antibody testing of COVID-19. Others (28/45, 62.2%) did not have any test of COVID-19. We collected all respondents' treatments and behaviours to prevent COVID-19. (19/23) had received the second dose. The majority of respondents kept their behaviours same as before receiving vaccines, such as "hand washing rates" (20/23, 95.24%), social distance" (18/23, 85.7%), and "masks in public places" (17/23, 80.95%), details in Table 3 . In addition, for considering the anxiety of COVID, 47.6% (10/21) respondents were much more reassured after the vaccination; 14.3% (3/21) were relieved a little, and 38.1% (8/21) had no change. Since 2020, COVID-19 is still currently one of the most important public health challenges to populations worldwide [49] . Numerous studies have focused on hospitalized patients who infected with novel coronavirus [50-52], but there have been fewer studies on the general population in the community. Therefore, our survey has filled up the data from the general population in China, so as to explore and understand behavioural habits change and conditions of the general population during the COVID-19 pandemic in China. First and foremost, we used wjx.cn platform to support the identification of unique visitor by IP addresses, it helped to calculate the respondent rate. The response rate was only 67.8%, which seemed to be low. As the results of a meta-analysis study showed that there was a greater chance of response when patients were presented with a comparatively shorter questionnaire [53] . This is a comprehensive survey covering diagnosis, treatment, outcome for one week and two weeks, and preventive measure. However, it takes more than 30 minutes which might be a challenge with behaviour -17 -fatigue and people reluctant to complete more surveys. People faced increasing COVID-19 questionnaires since 2020, so they may have experienced behaviour fatigue and were reluctant to complete more surveys. Furthermore, considering the online questionnaire, the respondents were particularly easily distracted during the answering process, so they could not concentrate on for a long time. For geographical distribution of respondents, we tried to include people from as many provinces and municipalities in China as possible, so only several areas were missing. Considering the interpersonal relationship of all authors and our dissemination strategy, the respondents from different geographic areas were nearly correlated to the prevalence rate of COVID-19 in various areas in 2020. The total number of respondents varied between different regions, and among them, Hubei province was the highest. This could be due to the tendency of people in Hubei province who suffered most in COVID-19 and were willing to make a contribution to scientific research. Our findings indicated that 86.8% respondents did not have any respiratory symptoms since the beginning of the COVID-19 outbreak. As China has benefited from the effective implementation of epidemic prevention and control policies, there were few cases of COVID-19 and so data collected on treatment, prevention and treatment outcomes were limited. Table 2 and Table 3 listed. For the special population, due to limited data from nine pregnant women among our respondents, we cannot find any special treatment or prevention from them. However, the safety of pregnant women and fetuses should still be noticed, including susceptibility and prognoses and the effects of the infection on the fetuses. Previous studies have shown that the severity of the disease in pregnant women was not yet apparent, and COVID-19 did not increase the rate of miscarriage, stillbirth, preterm labor or teratogenicity, and no unequivocal evidence support the fetal infection by intrauterine vertical transmission of SARS-CoV-2 [62-65], but there are still more and more reports of maternal deaths due to [66] [67] . Consequently, we still need to keep in mind that pregnant women and neonates require special attention regarding the prevention, diagnosis and management of COVID-19 to achieve health equity. Differing from a large number of previous clinical studies focusing on patients [48] [49] [50] , we aimed at a wide range of situation by followed general population in community, so we can explore the issues from a multi-dimensional perspective. Besides, in the process of localisation of the questionnaire, we fully considered However, there were also several limitations in our study. The questionnaire sample was not as large as we had planned and the respondent rate was low. If questionnaires could have been distributed in the early stage of the outbreak, the information obtained would have been richer. Considering the most (89.0%, 138/155) of participants responded to the question of their occupations during COVID-19 since -21 -2020 were healthcare workers and nearly a half of participants did not respond any information, we failed to collect various residents due to the dissemination scope and communication from the authors working in the field of health care. If we could disseminate the survey via communities and primary care, the results and sample may be different. The primary healthcare providers can be the good way to collect various data. In addition, longitudinal associations can be studied in future in order to have a more comprehensive understanding of the issue, such as the association between preventative behaviour and subsequent illness, the association between treatments taken and illness outcomes, the association between disease course and mental statement, and so forth. Further exploratory analyses can inspire creative topics for future public health developments, as well as further pre-clinical and clinical research. In summary, we found evidence of widespread use of infection control behaviours and modern medicines and TCM for treatment and prevention of COVID-19 and respiratory symptoms, especially many TCM preparations recommended in Chinese clinical guidelines. TCM still need to be identified their efficacy in further robust evidence. Larger scale studies including a more representative sample are needed to confirm our findings. The authors declare that there is no conflict of interest regarding the publication of this article. Adding Chinese herbal medicine to antibiotic treatment for acute exacerbation of chronic obstructive pulmonary disease (Grant No. 2018YFE0102300). This study was approved by the Research Ethics Board at Beijing University of Chinese Medicine, Beijing, China (No. 2020BZYLL0501). The data will be made available upon request. Accessed August 10, 2021. 2．National Health Commission of the People's Republic of China Beijing, China: National Health Commission of the People's Republic of China, National Administration of Traditional Chinese Medicine; 2020. 3．National Health Commission of the People's Republic of China Beijing, China: National Health Commission of the People's Republic of China, National Administration of Traditional Chinese Medicine; 2020 4．National Health Commission of the People's Republic of China Beijing, China: National Health Commission of the People's Republic of China, National Administration of Traditional Chinese Medicine; 2020. 5．National Health Commission of the People's Republic of China Beijing, China: National Health Commission of the People's Republic of China, National Administration of Traditional Chinese Medicine; 2020. 6．National Health Commission of the People's Republic of China Beijing, China: National Health Commission of the People's Republic of China, National Administration of Traditional Chinese Medicine; 2020. 7．National Health Commission of the People's Republic of China Beijing, China: National Health Commission of the People's Republic of China, National Administration of Traditional Chinese Medicine Clinical management of COVID-19: living guidance 25 Clinical Characteristics of Coronavirus Disease 2019 in China 10．WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19 Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev The COVID-19 vaccine tracker and landscape compiles detailed information of each COVID-19 vaccine candidate in development by closely monitoring their progress through the pipeline. Geneva: World Health Organization; 2021. 17．National Health Commission of the People's Republic of China. Novel Coronavirus Vaccine Technical Guide Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials tolerability, and immunogenicity of an inactivated SARS CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial tolerability, and immunogenicity of an inactivated SARS Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-inhuman trial Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled Evaluation of the safety profile of COVID-19 vaccines: a rapid review Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Impact of COVID-19 control measures on the spread of influenza Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia Coronavirus vaccine development: from SARS and MERS to COVID-19 A living systematic review of the psychological problems in people suffering from COVID-19 COVID-19 and mental health: A review of the existing literature Pregnancy and COVID-19: management and challenges Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records neonates born to mothers with 2019-nCoV pneumonia First COVID-19 maternal mortality in the UK associated with thrombotic complications The tragedy of COVID-19 in Brazil: 124 maternal deaths and counting